Cat FIV and FeLV Explained

Breed Identification

Cat FIV and FeLV Explained

FĒLIS Editorial Feb 2026 22 min read

FIV and FeLV always show up together. Together on the same test strip, together in the same article, together in the reasons shelters give for refusing adoption. Both are retroviruses, both go after the immune system, and that is where the similarity ends. FIV is a Lentivirus, a slow virus, in the same genus as HIV, following a path of infiltration, latency, and slow erosion. FeLV is a Gammaretrovirus, and many viruses in this genus share a common talent: causing cancer. FeLV does not just suppress the immune system. It can directly initiate malignant transformation inside a cat's body. The gap between these two viruses in terms of pathogenic logic is too wide for them to be bundled into the same management framework.

Buried in the cat genome

This section is the foundation for understanding why FeLV is so complex. Most popular science articles never touch this layer, and it is precisely at this layer that the difference between FeLV and FIV becomes most fundamental.

Every domestic cat's genome contains a set of sequences called enFeLV, endogenous FeLV. Millions of years ago, an ancestral version of FeLV infected a distant ancestor of the cat family, and the provirus happened to integrate into germ cell DNA. From that point on it was passed down through reproduction, generation after generation, fossilized into the genome of every modern house cat. Whether a cat lives on the thirtieth floor of an apartment and has never seen another cat, or has spent its life fighting behind dumpsters, enFeLV is in there. These sequences are incomplete. They cannot replicate on their own. They do not cause disease.

The trouble comes when they get borrowed.

When a cat is infected with the currently circulating exogenous FeLV (mainly FeLV-A, the subgroup with the highest transmission efficiency in nature), the exogenous virus's genome can recombine with these dormant endogenous sequences that have been sleeping in the host cell for millions of years. Recombination is a molecular event: two nucleic acid sequences from different origins undergo template switching during replication, exchanging fragments, assembling a new sequence. This process requires no external intervention. It is a "design flaw" inherent to the retroviral replication mechanism itself. Among the recombination products, the most studied is FeLV-B, which has a broader receptor usage profile than FeLV-A, can infect more cell types, and has a tighter association with lymphoma.

What does this mean. It means FeLV's disease spectrum is not determined by a single virus, but by what kind of recombination occurs between the exogenous virus and the ancient remnants in the host genome. The completeness and genomic location of enFeLV sequences vary subtly between different cats. The sequences carried by different exogenous FeLV strains also vary. The recombination products that come out are therefore endlessly variable. This directly explains a clinical observation that has puzzled veterinarians for decades: why two cats with identical FeLV progressive infection status can take completely different paths, one developing lymphoma, another developing severe anemia, a third starting with immune-mediated hemolysis before tumors appear. It is not because "individual variation" as a four-word handwave is a sufficient explanation. It is because the virus variants actually running inside their bodies are different at the molecular level.

Beyond FeLV-B, recombination can also produce FeLV-C and FeLV-D subgroups. The association between FeLV-C and pure red cell aplasia has fairly robust experimental evidence. FeLV-D is relatively rare, with a receptor usage mechanism distinct from the other three. The entire complexity of the FeLV subgroup ecology is rooted in the enFeLV recombination mechanism.

FIV has no corresponding endogenous sequences. The domestic cat genome contains no ancient FIV fossils. When FIV enters a cat, it is just itself. It does not reassemble into new versions by borrowing parts from the host DNA. Its pathogenic mechanism is comparatively linear: infect CD4+ T cells, slowly consume, immune function gradually declines. This linearity is relative to FeLV's multidimensional, multi-variant, unpredictable complexity.

FIV does have another characteristic: neurotropism. The virus crosses the blood-brain barrier and infects microglia in the central nervous system, potentially triggering low-grade neuroinflammation in the early stages of infection. The outward signs are extremely subtle: slightly quieter than before, half a beat slower in responding to stimuli, minor shifts in sleep patterns. No cat owner would attribute these to a virus. No veterinarian screens for this in a routine exam. There is substantial documentation of FIV neurotropism in the research literature. Attention to it at the clinical and popular science level is essentially zero. This is a cognitive gap that should not exist.

Transmission

FIV

FIV is transmitted through deep bite wounds. Viral concentration in saliva is high, but it needs to penetrate the skin into subcutaneous tissue and blood to establish infection. Grooming, shared food bowls, sneeze droplets do not pose a meaningful risk. The core epidemiological scenario for FIV boils down to one thing: unneutered male cats biting each other over territory.

FeLV

FeLV spreads through saliva, nasal secretions, urine, feces, and milk. No wound needed. Sharing a water bowl and mutual grooming are sufficient.

FIV-positive cats can live with FIV-negative cats. The ISFM and AAFP guidelines are clear on this, provided the cat group is stable and there is no aggressive biting. Numerous rescue organizations ignore this consensus and continue labeling FIV cats as "must be housed alone." Some euthanize directly. These practices are not defensible under the current evidence. This is not a matter of being "perhaps a bit conservative." It is wrong. Wrong in treating a slow virus transmitted through fighting bites as a highly contagious plague, and cats pay the price. FeLV-positive cats and negative cats, on the other hand, must be physically separated.

The lions of the Serengeti and the panthers of Florida

This section matters because it provides an independent calibration point outside of domestic cat clinical data, and the conclusion it points toward is enough to destabilize the default narrative that "FIV is a deadly virus."

FIV is not exclusive to domestic cats. Lions carry FIVple, cougars carry FIVpco, cheetahs, leopard cats, various wildcats all have their own corresponding FIV variants. FIV prevalence in the Serengeti lion population exceeds 90%. If FIV were the kind of deadly "feline AIDS" virus that most popular articles imply, these prides could not have survived. The vast majority of these highly infected lions show no signs of immune collapse, reproduce normally, and do not have significantly shortened lifespans.

Over 90% prevalence, extremely low pathogenicity. These numbers force a question that cannot be sidestepped: under what conditions is FIV actually dangerous?

One explanation is that the coexistence between lions and FIV has been long enough for natural selection to weed out the high-virulence strains, leaving behind low-virulence variants that have reached some kind of compromise with the host. Another explanation focuses on the host side: through prolonged coevolution, the lion immune genetic background has accumulated enough resistance alleles to suppress FIV's pathogenic potential to subclinical levels. The two explanations are not mutually exclusive and are likely both at work.

Regardless of which explanation holds, the inference points in the same direction: FIV's pathogenicity is not an inherent fixed property of the virus. It is a function jointly determined by the virus, the host's immune genetic background, and environmental conditions. Domestic cats may have a much shorter coexistence history with FIV, with coevolution not yet having reached equilibrium, which is why pathogenicity remains more apparent. Within domestic cat populations, the immune genetic background varies considerably between individuals, which partly explains why some FIV-positive cats reach fifteen with nothing wrong while others start developing problems at seven or eight.

This perspective from wildlife biology repositions FIV, more powerfully than any clinical dataset, from "terrifying feline AIDS" to "a host-pathogen relationship where coevolution has not yet reached equilibrium." It does not deny that FIV can cause serious consequences at the individual level. What it denies is the assumption that FIV inherently equals a death sentence.

FeLV in wild felids tells a completely different story. Between 2002 and 2004, FeLV broke out in the Florida panther population. That population at the time consisted of fewer than 100 individuals, already extremely vulnerable due to habitat fragmentation and inbreeding depression. FeLV directly killed multiple animals. This event is well documented because the Florida panther is a flagship species in the U.S. federal endangered species protection program, with tracking data on every individual. FeLV maintained its high destructive capacity even after jumping to a different host species. It did not trend toward coexistence the way FIV did in lion populations.

How FeLV manufactures tumors

This section deserves expansion because the oncogenic mechanism of FeLV is the most essential dividing line between it and FIV.

When FeLV provirus integrates into host DNA, the insertion site is not entirely random. The LTR at each end of the viral genome contains enhancers and promoters: a set of switches that can forcibly activate gene transcription. When these switches happen to land near a host proto-oncogene (c-myc being the most studied), normal regulation is bypassed, the proto-oncogene is aberrantly activated, and the cell is pushed onto the track of malignant transformation. This is insertional mutagenesis. Add the FeLV-B and other variants produced by the enFeLV recombination mechanism discussed earlier, which further broaden cell tropism, and tumors can arise in a wider range of tissue types.

FIV does not take this path. FIV provirus, once integrated, does not activate host proto-oncogenes through its LTR. FIV-associated tumors are more often an indirect consequence of failing immune surveillance, which is a fundamentally different mechanism from FeLV's direct molecular-level oncogenic drive. This distinction has a straightforward clinical implication: FeLV-positive cats face not only the passive risk of "getting sick more easily" but also an active oncogenic pressure originating from the virus itself. This is a threat dimension that FIV-positive cats do not have to confront.

The fork in the road during FeLV infection

FeLV enters through the mouth and nose, establishes its initial replication site in the oropharyngeal lymphoid tissue, then hitches a ride on monocytes and lymphocytes into the bloodstream and disseminates throughout the body. The fate-determining checkpoint: whether the virus can breach into the bone marrow and infect hematopoietic stem cells.

Regressive infection

If it cannot get in, the outcome is regressive infection. p27 turns negative, proviral DNA may persist in the genome in a transcriptionally silent state.

Progressive infection

If it does get in, the outcome is progressive infection: provirus integrates into the DNA of hematopoietic stem cells, and every blood cell descendant thereafter carries the viral genetic information. Irreversible.

Cats with progressive infection face simultaneous attacks from multiple directions: insertional mutagenesis leading to cancer; bone marrow suppression causing anemia and pancytopenia; immune dysregulation triggering hemolysis and thrombocytopenia; widespread opportunistic infections. Median survival time is around 2 to 3 years. The prognosis is not on the same level as FIV.

The long latency of FIV

FIV attacks CD4+ T cells. The acute phase may involve brief fever and lymph node swelling, which in most cases goes unnoticed. Then comes a latency period lasting years to over a decade. CD4 counts decline slowly, at a rate that varies enormously between individuals. Some cats sustain the standoff with the virus well into their teens and ultimately die of causes entirely unrelated to FIV. Management conditions (indoor housing, low stress, nutrition, exam frequency, speed of treating secondary infections) carry extremely high weight in determining prognosis.

Vaccines and treatment

FeLV vaccine is recommended for cats with outdoor exposure risk. Initial kitten series, then booster frequency based on risk assessment. Injection site: left hind limb, distal to the knee, because adjuvanted vaccines have an epidemiological association with FISS (injection-site sarcoma). Distal limb placement means that if a tumor develops, amputation can achieve curative resection. Protection rates vary between products, can reduce the incidence of progressive infection, cannot completely block transient viremia.

FIV has no vaccine available. Fel-O-Vax FIV was discontinued. Limited efficacy plus post-vaccination antibodies that interfere with diagnostic testing. FIV has at least five major subtypes, clades A through E, with poor cross-protection between them. Structurally identical to the HIV vaccine development impasse.

Treatment options are very limited. AZT is used in both FIV and FeLV cats, constrained by bone marrow suppression. Interferon omega is available in Europe and Japan, not in North America, with contested efficacy. Bone marrow transplant makes theoretical sense for FeLV progressive infection. Obstacles are overwhelming: immature FLA typing system, high-risk myeloablative conditioning, virtually no experience managing GVHD in cats. Will not leave the laboratory in the foreseeable future. CRISPR excision of provirus is conceptually sound, with delivery efficiency as the core bottleneck. Far from clinical application.

The mouth: the underestimated battlefield on FIV cats

FIV-positive cat daily management (indoor housing, neutering, low stress, no raw meat, regular checkups) is the baseline. FeLV cat management centers on monitoring bone marrow and screening for tumors, with CBC every three to six months, and any weight loss, lymph node enlargement, recurrent fever, or sustained appetite decline warranting immediate further investigation. Physical separation between FeLV cats and negative cats has no room for compromise. FeLV cats have a broader and more severe opportunistic infection profile, and the breakthrough of GS-441524 in FIP treatment is a direct benefit for FeLV cats.

These are all standard recommendations, and stating them is stating them. The following issue is not standard and has no settled conclusion, and is worth the space to lay out.

FIV-positive cats develop chronic lymphocytic plasmacytic stomatitis at a rate far higher than the general cat population. This stomatitis can become severe enough that opening the mouth causes pain and eating becomes impossible. The posterior oral mucosa shows diffuse proliferative inflammation that bleeds at the slightest contact. The impact on quality of life is direct, continuous, every moment of every day.

Full-mouth extraction is the most widely adopted treatment for refractory stomatitis. After removal of all teeth including retained roots, a substantial proportion of cats experience significant resolution or complete remission of inflammation. The efficacy of this procedure among the various treatment options for stomatitis is the most reliable, far more so than long-term corticosteroids or cyclosporine.

The prevailing approach is to wait. Wait for the stomatitis to progress to its severe stage. Wait until the cat can no longer eat. Wait until all conservative options have been tried and failed. Only then recommend full-mouth extraction. This is the decision pathway of many veterinarians. Is this pathway sound?

From the perspective of FIV immune management, the waiting period itself is causing damage. Chronic inflammation in the oral cavity consumes immune resources every day. The oral mucosa, damaged by inflammation, is no longer an intact barrier. Oral bacteria repeatedly enter the bloodstream, creating intermittent bacteremia. For an immune system whose CD4 count is already on a slow downward trajectory, every additional unit of immune burden accelerates the decline. By the time the cat can no longer eat, its overall nutritional status has also deteriorated, general condition is worse, and the risks of anesthesia and surgery are actually higher.

Performing full-mouth extraction earlier, intervening at a stage when the stomatitis is moderate and the cat can still eat but is clearly in pain, may yield benefits on two fronts: removing the chronic inflammatory immune burden sooner, and operating when the cat is in better overall condition with lower anesthetic risk.

This is not a settled question. No prospective randomized controlled trial has compared the long-term outcomes of early full-mouth extraction versus waiting until severe in FIV cats. Such a trial may never be easy to conduct, given sample size requirements and ethics review barriers. What is presented here is reasoning based on the immunopathological logic of FIV, not an evidence-based conclusion. Its value lies in providing a thinking framework: in FIV cats, "let's watch and wait a bit longer" is not a zero-cost option. Waiting carries a cost, and that cost needs to be factored into the decision. Laying this tradeoff out in discussion with a veterinarian experienced in feline dentistry is worthwhile. The key point is not to let "let's keep observing" become the indefinite default.

On transmission to humans

FIV and FeLV are strictly cat-specific viruses. They do not infect humans. They do not infect dogs. Being bitten or scratched by an FIV cat presents no pathway for viral transmission to a person (routine bacterial wound care is a separate matter). In adoption consultations, this misunderstanding remains a common reason for rejecting FIV and FeLV-positive cats. There is no virological basis for this fear.

FIV-positive cats with proper management can live to a normal lifespan. FeLV progressive infection carries a substantially worse prognosis. Active monitoring and supportive care can still give these cats time with quality of life. A single line on a test strip does not equal an endpoint, especially when that line may be a false positive.